Cell-Based Therapy for Cardiac and Peripheral Arterial Disease - (0287)

Cigna considers transplantation of cells into the myocardium experimental/investigational/unproven for all indications and deems autologous intra-arterial or intra‑muscular bone marrow cell transplantation not medically necessary for peripheral arterial disease and other occlusive conditions, listing specific CPT (e.g., 33999, 38206, 38232, 93799) and HCPCS (e.g., C9782, S2150) codes as investigational or not medically necessary. Claims must use appropriate covered diagnosis/procedure codes (services billed without covered codes will be denied), documentation of IDE study participation is required when billing IDE‑related HCPCS (e.g., C9782), and medical director review with supporting clinical documentation will be performed for individual requests.

"Transplantation of cells into the myocardium is considered experimental, investigational or unproven for ANY indication."